Revenue Update on Onconova Therapeutics Inc(NASDAQ:ONTX)

Onconova Therapeutics Inc(NASDAQ:ONTX) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during Pre-Market on Mar 27, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Earnings per share were $-0.54.

Onconova Therapeutics Inc (ONTX) made into the market gainers list on Fridays trading session with the shares advancing 6.34% or 0.18 points. Due to strong positive momentum, the stock ended at $3.02, which is also near the day’s high of $3.0283. The stock began the session at $2.86 and the volume stood at 47,449 shares. The 52-week high of the shares is $8.17 and the 52 week low is $2.11. The company has a current market capitalization of $20 M and it has 67,59,895 shares in outstanding.

Onconova Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways important to cancer cells. It has three clinical-stage product candidates and many preclinical programs that target kinases cellular metabolism or cell division. The Company’s lead product candidate rigosertib is being tested as a single agent and in combination with azacitidine in clinical trials of patients with myelodysplastic syndromes (MDS) and related cancers. The Company is continuing the Phase II portion of a clinical trial of rigosertib oral in combination with azacitidine for patients with MDS and acute myelogenous leukemia (AML).

Add Comment